An Open, Single Dose Designed Clinical Study to Evaluate Safety and Pharmacokinetic/Pharmacodynamic Characteristics After Oral Administration of URC102 in Patients With Renal Impairment Under Fasted Conditions and Healthy Adult Volunteers Under Fasted and Fed Conditions
Latest Information Update: 08 Dec 2022
At a glance
- Drugs URC 102 (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors JW Pharmaceutical
Most Recent Events
- 04 Dec 2022 Status changed from recruiting to completed.
- 03 Jun 2022 Planned End Date changed from 1 May 2022 to 1 Jul 2022.
- 03 Jun 2022 Planned primary completion date changed from 1 May 2022 to 1 Jul 2022.